Skip to main content
Frontier Biotechnologies Inc. logo

Frontier Biotechnologies Inc. — Investor Relations & Filings

Ticker · 688221 ISIN · CNE100005XF5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2022-08-30 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688221

About Frontier Biotechnologies Inc.

https://www.frontierbiotech.com/

Frontier Biotechnologies Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative medicines, particularly in the field of anti-infectives. The company's flagship product is albuvirtide, a long-acting HIV fusion inhibitor administered via injection. This therapeutic represents a significant advancement in HIV management by providing a long-acting alternative to daily oral regimens. Frontier Biotechnologies maintains a diverse pipeline of clinical-stage candidates, including protease inhibitors developed for the treatment of COVID-19. The company leverages its proprietary technology platforms to develop long-acting peptide drugs and small molecule therapeutics targeting unmet medical needs in infectious diseases and chronic conditions. Its core operations encompass the full drug development lifecycle, from discovery and clinical trials to manufacturing and commercial distribution.

Recent filings

Filing Released Lang Actions
前沿生物2022年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2022 半年度报告摘要' which translates to '2022 Half-Year Report Summary'. It contains detailed financial data such as total assets, net profit, earnings per share, and shareholder information for the half-year period. The document explicitly states it is a half-year report summary and references the full half-year report for comprehensive details. The length is 3265 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or a link to a report. The document is unaudited and includes management discussion of risks and financial performance. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data and analysis. Therefore, the correct classification is IR with high confidence. H1 2022
2022-08-30 Chinese
中信证券股份有限公司关于前沿生物药业（南京）股份有限公司2022年度以简易程序向特定对象发行A股股票之上市保荐书
Capital/Financing Update Classification · 95% confidence The document is a detailed listing sponsorship letter (上市保荐书) related to a 2022 year-end simplified procedure private placement of A shares by Frontier Biotechnologies (Nanjing) Co., Ltd. It includes extensive company background, business and financial data, risk disclosures, issuance details, pricing, subscription, and use of proceeds. The document is lengthy (15,000 characters) and contains substantive financial data, business descriptions, and issuance specifics. It is not a brief announcement or a certification letter but a comprehensive report related to a capital raising event via private placement. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes through a private placement of shares.
2022-08-25 Chinese
中信证券股份有限公司关于前沿生物药业（南京）股份有限公司2022年度以简易程序向特定对象发行A股股票之发行保荐书
Capital/Financing Update Classification · 95% confidence The document is titled as an "发行保荐书" (Sponsorship Letter) related to a 2022 issuance of A shares by Frontier Biotech (Nanjing) Co., Ltd. It is issued by CITIC Securities as the sponsor for the issuance and listing on the Shanghai Stock Exchange STAR Market (科创板). The content includes detailed information about the issuer, the sponsor, shareholding structure, financial data, regulatory approvals, and compliance with securities laws and listing rules. It is a formal sponsorship document required for a specific securities issuance and listing process, not a general financial report or earnings release. It is not an announcement of a report but a substantive application and sponsorship document for a capital raising event. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length is substantial (15,000 characters), and it contains detailed substantive information about the issuance and related parties, consistent with a financing update rather than a simple announcement or regulatory filing.
2022-08-25 Chinese
前沿生物药业（南京）股份有限公司2022年度以简易程序向特定对象发行A股股票募集说明书（注册稿）
Capital/Financing Update Classification · 100% confidence The document is titled as a "募集说明书" which translates to a "Prospectus" or "Offering Circular" for a specific stock issuance. It is for the year 2022 and relates to a simplified procedure for a targeted issuance of A shares by Frontier Biotechnologies (前沿生物药业). The content includes detailed information about the issuer, shareholders, business model, risk factors, and legal statements. It is a comprehensive document related to a capital raising event through a share issuance to specific investors. This fits the category of a Capital/Financing Update, as it is an update on the company's fundraising activity and capital structure changes. The document is lengthy (15,000 characters) and contains substantive information about the issuance, not just an announcement or a brief summary. Therefore, the correct classification is Capital/Financing Update (CAP).
2022-08-25 Chinese
国浩律师（南京）事务所关于前沿生物药业（南京）股份有限公司2022年度以简易程序向特定对象发行A股股票之法律意见书
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding a 2022 simplified procedure private placement issuance of A shares by a listed company, including approvals, authorizations, issuance details, pricing, subscription, and regulatory compliance. It references the issuance of shares, the registration approval by the China Securities Regulatory Commission (CSRC), and the Shanghai Stock Exchange (SSE) Sci-Tech Innovation Board listing. The document contains substantive legal and procedural details about the capital raising and issuance process, including shareholder meeting approvals, board resolutions, pricing, subscription agreements, and regulatory compliance. This is not a simple announcement or a brief summary but a comprehensive legal opinion related to a capital/financing event. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is not a mere announcement or certification but a full legal opinion on the financing transaction.
2022-08-25 Chinese
前沿生物关于以简易程序向特定对象发行股票申请获得中国证监会注册批复的公告
Capital/Financing Update Classification · 100% confidence The document is an announcement from a company about receiving approval from the China Securities Regulatory Commission (CSRC) for a simplified procedure to issue shares to specific investors. It mentions registration approval for a share issuance and outlines compliance and procedural requirements. The document is short (616 characters) and focuses on a capital raising event through share issuance. This fits the definition of a Capital/Financing Update (CAP) as it relates to company fundraising and capital structure changes. It is not a full financial report or an announcement of a report publication, but a direct announcement of a financing event.
2022-08-25 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.